UY37587A - Tratamiento de mucopolisacaridosis i con alfa-l-iduronidasa (idua) humana glicosilada completamente humana - Google Patents
Tratamiento de mucopolisacaridosis i con alfa-l-iduronidasa (idua) humana glicosilada completamente humanaInfo
- Publication number
- UY37587A UY37587A UY0001037587A UY37587A UY37587A UY 37587 A UY37587 A UY 37587A UY 0001037587 A UY0001037587 A UY 0001037587A UY 37587 A UY37587 A UY 37587A UY 37587 A UY37587 A UY 37587A
- Authority
- UY
- Uruguay
- Prior art keywords
- human
- idua
- mucopolisacaridosis
- iduronidasa
- glicosilated
- Prior art date
Links
- 102100035028 Alpha-L-iduronidase Human genes 0.000 title abstract 3
- 101001019502 Homo sapiens Alpha-L-iduronidase Proteins 0.000 title abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 108010003381 Iduronidase Proteins 0.000 abstract 1
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 abstract 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01076—L-Iduronidase (3.2.1.76)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describen composiciones y métodos para la administración de una a-L-iduronidasa (IDUA) glicosilada completamente humana (HuGly) al líquido cefalorraquídeo del sistema nervioso central (SNC) de un sujeto humano con diagnóstico de mucopolisacaridosis I (MPS I).
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762452769P | 2017-01-31 | 2017-01-31 | |
US201762485655P | 2017-04-14 | 2017-04-14 | |
US201762529366P | 2017-07-06 | 2017-07-06 | |
US201762579690P | 2017-10-31 | 2017-10-31 | |
US201862616234P | 2018-01-11 | 2018-01-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY37587A true UY37587A (es) | 2018-08-31 |
Family
ID=63041038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001037587A UY37587A (es) | 2017-01-31 | 2018-01-30 | Tratamiento de mucopolisacaridosis i con alfa-l-iduronidasa (idua) humana glicosilada completamente humana |
Country Status (12)
Country | Link |
---|---|
US (2) | US20190358303A1 (es) |
EP (1) | EP3576768A4 (es) |
JP (1) | JP2020508289A (es) |
KR (1) | KR20190109506A (es) |
AU (1) | AU2018216807A1 (es) |
BR (1) | BR112019015482A2 (es) |
CA (1) | CA3049915A1 (es) |
IL (1) | IL268076B1 (es) |
MA (1) | MA47436A (es) |
SG (1) | SG11201906452PA (es) |
UY (1) | UY37587A (es) |
WO (1) | WO2018144441A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112020000063A2 (pt) | 2017-07-06 | 2020-07-14 | The Trustees Of The University Of Pennsylvania | terapia gênica mediada por aav9 para tratamento de mucopolissacaridose tipo i |
CA3076036A1 (en) | 2017-09-22 | 2019-03-28 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
KR20210034037A (ko) * | 2018-07-18 | 2021-03-29 | 리젠엑스바이오 인크. | 완전-인간 글리코실화된 인간 알파-l-이두로니다아제 (idua)를 사용한 점액다당류증 i의 치료 |
EP4093428A1 (en) * | 2020-01-22 | 2022-11-30 | RegenxBio Inc. | Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua) |
CA3209779A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
CA3236188A1 (en) * | 2021-10-27 | 2023-05-04 | The University Of North Carolina At Chapel Hill | Aav-idua vector for treatment of mps i |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196315A (en) * | 1990-05-01 | 1993-03-23 | The Johns Hopkins University | Human neuronal cell line |
AU649897B2 (en) * | 1991-11-14 | 1994-06-02 | Women's And Children's Hospital | Synthetic alpha-L-iduronidase and genetic sequences encoding same |
TWI235158B (en) * | 1997-09-01 | 2005-07-01 | Kirin Brewery | Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same |
IL139616A0 (en) * | 1998-05-13 | 2002-02-10 | Harbor Ucla | Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating, diseases caused by deficiencies thereof |
US6426208B1 (en) * | 1999-11-12 | 2002-07-30 | Harbor-Ucla Research And Education Institute | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
US6585971B1 (en) * | 1999-11-12 | 2003-07-01 | Harbor-Ucla Research And Education Institute | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof |
JP2004504016A (ja) * | 2000-06-30 | 2004-02-12 | マキシゲン・エイピーエス | ペプチド拡張されたグリコシル化ポリペプチド |
US9375440B2 (en) * | 2006-11-03 | 2016-06-28 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
CN115120745A (zh) * | 2013-05-15 | 2022-09-30 | 明尼苏达大学董事会 | 腺相关病毒介导的基因向中枢神经系统转移 |
ES2745566T3 (es) * | 2013-06-11 | 2020-03-02 | Portage Pharmaceuticals Ltd | Estructura, fabricación y usos de péptidos que pueden penetrar en las células derivados de seres humanos conjugados con péptidos de carga biológicamente activos específicos |
WO2015009961A1 (en) * | 2013-07-19 | 2015-01-22 | Armagen Technologies, Inc. | Compositions and methods related to structures that cross the blood brain barrier |
EP3209306B1 (en) * | 2014-10-20 | 2024-04-24 | Neuralstem, Inc. | Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof |
JP2017534640A (ja) * | 2014-11-10 | 2017-11-24 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | アルファ−l−イズロニダーゼ、イズロン酸−2−スルファターゼおよびアルファガラクトシダーゼaの治療用組成物ならびにそれらの使用方法 |
-
2018
- 2018-01-30 US US16/482,057 patent/US20190358303A1/en not_active Abandoned
- 2018-01-30 SG SG11201906452PA patent/SG11201906452PA/en unknown
- 2018-01-30 KR KR1020197025133A patent/KR20190109506A/ko not_active Application Discontinuation
- 2018-01-30 EP EP18748381.3A patent/EP3576768A4/en active Pending
- 2018-01-30 UY UY0001037587A patent/UY37587A/es unknown
- 2018-01-30 IL IL268076A patent/IL268076B1/en unknown
- 2018-01-30 CA CA3049915A patent/CA3049915A1/en active Pending
- 2018-01-30 JP JP2019541264A patent/JP2020508289A/ja active Pending
- 2018-01-30 MA MA047436A patent/MA47436A/fr unknown
- 2018-01-30 AU AU2018216807A patent/AU2018216807A1/en active Pending
- 2018-01-30 WO PCT/US2018/015910 patent/WO2018144441A1/en unknown
- 2018-01-30 BR BR112019015482-5A patent/BR112019015482A2/pt unknown
-
2023
- 2023-10-03 US US18/480,172 patent/US20240050537A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20240050537A1 (en) | 2024-02-15 |
SG11201906452PA (en) | 2019-08-27 |
MA47436A (fr) | 2019-12-11 |
KR20190109506A (ko) | 2019-09-25 |
EP3576768A1 (en) | 2019-12-11 |
US20190358303A1 (en) | 2019-11-28 |
EP3576768A4 (en) | 2020-11-04 |
CA3049915A1 (en) | 2018-08-09 |
IL268076B1 (en) | 2024-06-01 |
IL268076A (en) | 2019-09-26 |
WO2018144441A1 (en) | 2018-08-09 |
AU2018216807A1 (en) | 2019-08-08 |
BR112019015482A2 (pt) | 2020-03-31 |
JP2020508289A (ja) | 2020-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY37587A (es) | Tratamiento de mucopolisacaridosis i con alfa-l-iduronidasa (idua) humana glicosilada completamente humana | |
CL2018001372A1 (es) | Moléculas de anticuerpo contra april y usos de las mismas | |
EA201792613A1 (ru) | Модуляторы cot и способы их применения | |
EA201792547A1 (ru) | Популяции бактерий для стимуляции состояния здоровья | |
EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
EA201692529A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
EA201791866A1 (ru) | Бициклические гетероциклы в качестве ингибиторов fgfr | |
MA51815A (fr) | Méthodes de traitement ou de prévention de migraines avec anticorps contra le receptor de cgrp | |
BR112016016158A2 (pt) | Derivados de heterociclila bicíclicos como inibidores de irak4, sua composição farmacêutica e seus usos | |
EA201691582A1 (ru) | Новые фармацевтические препараты | |
BR112017003863A2 (pt) | “modulador óptico e sistema óptico modulador de múltiplos segmentos” | |
BR112017008659A2 (pt) | ?métodos e compostos de agonista de gip? | |
BR112017018181A2 (pt) | plugue médico e conector de engate para estabelecer uma comunicação fluida entre dois sistemas. | |
EA201692031A1 (ru) | Фармацевтическая композиция с активным действием в отношении хронических бактериальных инфекций | |
CL2019002251A1 (es) | Anticuerpos contra triptasa, composiciones de estos y usos de estos. | |
UY37679A (es) | Tratamiento de mucopolisacaridosis ii con iduronato-2-sulfatasa (ids) humana recombinante producida por células neurales o gliales humanas | |
EA201792612A1 (ru) | 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot | |
MX2019006281A (es) | Cartuchos de filtro tubulares y ovoides y sistemas de filtro que los utilizan. | |
MX2019002924A (es) | Composiciones purificadas de oligosacaridos de leche humana. | |
MX2016006688A (es) | Inhibidores tetraciclicos de autotaxina. | |
PH12016502530A1 (en) | Pharmaceutical compositions comprising dgla and use of same | |
UY36173A (es) | Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia | |
FR3022139B1 (fr) | Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee | |
BR112022014563A2 (pt) | Método para tratamento de um sujeito humano diagnosticado com mucopolissacaridose i (mps i) | |
EA202090270A1 (ru) | Новые замещенные производные ксантина |